NCT07737522尚未招募2 期
Myocardial Metabolic Flux in Patients With Pulmonary Arterial Hypertension (PAH) in Response to GLP-1 Agonist Therapy: a Physiological Study Using 31-Phosphorus MR Spectroscopy
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 32
- 主要终点
- Change in the phosphocreatine-to-adenosine triphosphate (31PCr/ATP) ratio between baseline and follow up in response to treatment with GLP-1 agonist
研究概览
简要总结
The rationale for this study is that GLP-1 agonist treatment is likely to influence myocardial substrate utilisation, changing the predominant source of metabolic energy within the heart to a more energetically efficient form. This is represented by a surrogate for improved mitochondrial efficiency with reduction in myocardial lactate levels (produced by inefficient myocardial glycolysis, prevalent in the ventricles of patients with pulmonary hypertension), which can be measured by 31P-magnetic resonance spectroscopy (31P-MRS).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of Group 1 PAH confirmed by right heart catheterisation under the National Pulmonary Hypertension Service, Royal Brompton Hospital, part of GSTT Foundation Trust
- •Age over 18, less than 85 years
- •Able to give informed consent
- •On a stable dose of PAH-specific therapies (e.g., ERA, PDE5i) for at least 3 months.
- •5. Clinically justified prescription of GLP-1 agonist Semaglutide based on following criteria: BMI > 30 or BMI > 27 with at least one cardiovascular co-morbidity (systemic hypertension, diabetes, pre-diabetes, COPD, atrial fibrillation, dyslipidaemia, sleep disordered breathing)
排除标准
- •2. Myocardial infarction within the previous 3 months
- •3. Contraindications to MRI: Pacemakers, metallic implants, or severe claustrophobia.
- •4. Severe renal impairment: eGFR < 15ml/min/1.73m.
- •5. Current use of SGLT2 inhibitors or GLP-1 agonist therapy (which significantly alter fuel substrate preference) or insulin therapy that cannot be held for the fasting scan
结局指标
主要结局
Change in the phosphocreatine-to-adenosine triphosphate (31PCr/ATP) ratio between baseline and follow up in response to treatment with GLP-1 agonist
时间窗: 12 weeks
次要结局
未报告次要终点
研究者
相似试验
招募中
不适用
Cardiometabolic Disease and Substrate MetabolismPreeclampsiaGestational Diabetes Mellitus (GDM)Preeclampsia (PE)Preeclampsia (PE) RiskGestational DiabetesGestational Diabetes Mellitus in PregnancyCardiometabolic DiseasesPlacental DysfunctionPregnancyPregnancy ComplicationsGestational ComplicationsInsulin ResistanceNCT07565727University of Tennessee Graduate School of Medicine50
尚未招募
不适用
Expression of GLP1 Receptor on Peripheral Blood Mononuclear Cells in Advanced Peripheral Artery Disease: Paving the Way for GLP1R Agonists Treatment in Chronic Limb Threatening IschemiaNCT07340112University Hospital, Strasbourg, France50
招募中
2 期
Role of GLP1 RA Dulaglutide on Severe Intracranial AtherosclerosisNCT07282041National University of Singapore130
招募中
不适用
The Effect of Pharmacotherapy With GLP-1 and GIP/GLP-1 Analogs on Changes in Qualitative and Quantitative Parameters of the Diet as Well as Metabolic and Behavioral Parameters in Patients With Excess Body WeightNCT07270497Medical University of Warsaw100
尚未招募
不适用
Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric RetentionNCT07276763Fudan University16,509